Table 1 Baseline demographic and clinical characteristics of the included patients

Total

723

285

231

Ki-67

 ≥5% (high group)

167 (23.1%)

50 (17.5%)

-

 <5% (low group)

556 (76.9%)

235 (82.5%)

-

Sex

 Female

502 (69.4%)

203 (71.2%)

71 (30.7%)

 Male

221 (30.6%)

82 (28.8%)

160 (69.3%)

Age

56.0 (Range: 32–76)

53.1 (Range: 27–72)

43.9 (Range: 27–83)

Tumor volume (cm³)

36.6 (Range: 4.7–337.2)

32.2 (Range: 3.1–129.4)

3.2 (Range: 0.15–9.73)

Location

 Cerebral convexity

406 (56.2%)

141 (49.5%)

85 (36.8%)

 Falx

118 (16.3%)

47 (16.5%)

43 (18.6%)

 Skull base

199 (27.5%)

97 (34.0%)

103 (44.6%)

Laterality

 Left

308 (42.6%)

125 (43.9%)

97 (42.0%)

 Right

327 (45.2%)

136 (47.7%)

110 (47.6%)

 Midline

88 (12.2%)

24 (8.4%)

24 (10.4%)

WHO grade

 WHO I

540 (74.7%)

243 (85.3%)

-

 WHO II

156 (21.6%)

36 (12.6%)

-

 WHO III

27 (3.7%)

6 (2.1%)

Peritumoral edema

 EI = 1

372 (51.5%)

149 (52.3%)

209 (90.5%)

 1 < EI < 2

172 (23.7%)

52 (18.2%)

9 (3.8%)

 2 ≤ EI < 3

100 (13.8%)

53 (18.6%)

7 (3.0%)

 EI ≥ 3

79 (10.9%)

31 (10.9%)

6 (1.7%)

CSF cleft surrounding tumor

496 (68.6%)

207 (72.6%)

202 (87.4%)

Absent capsular enhancement

179 (24.8%)

29 (10.2%)

22 (9.5%)

Intra-tumoral necrosis

173 (23.9%)

60 (21.1%)

12 (5.2%)